Hou et al. (2019) revealed that flavonoid treatment inhibits recurring colitis and colitis-associated tumorigenesis; these flavonoids downregulate IL-1β and TNF-α and consequently inhibit inflammation-induced colorectal cancer in vitro [68]. The gene discussed is IL1B; the disease is colitis.